Teva ALS drug disappoints in Phase II trial

Talampanel was found to be safe, but the drug did not meet the study's clinical goals.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) said today that a Phase II clinical trial produced disappointing results for its Talampanel ALS drug.

The Phase II ALSTAR trial was designed to assess efficacy, safety and tolerability of Talampanel in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease) patients. Results indicated that while Talampanel was safe for ALS patients, the study did not meet its primary endpoint.

Teva group vice president - global branded products Moshe Manor said, "Despite our hopes to advance the treatment of this debilitating disease, Talampanel did not succeed in demonstrating the required efficacy, although safety was established."

Teva shares rose 1.16% to $57.46 in early Nasdaq trading, giving a market cap of $51.31 billion.

Published by Globes [online], Israel business news - - on May 17, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018